![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Nabumetone, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2006-092 - Rev 02
This Chemical Type CEP, issued on September 25, 2017, remains in force until September 10, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 1350 associated with this CEP further emphasizes